Tirzepatide is associated with a lower for achieving glycemic and weight loss goals compared to semaglutide 1 mg.
The cost per responder for tirzepatide to achieve HbA1c endpoints of ≤ 6.5% was lower for the 10 mg and 15 mg doses.
Tirzepatide demonstrated a lower cost for weight loss endpoints of ≥ 5%, ≥ 10%, and ≥ 15% across all doses.
No statistically significant differences were found in cost per responder for achieving HbA1c < 7% between tirzepatide and semaglutide for all doses.
All doses of tirzepatide had statistically significantly lower costs for achieving composite treatment endpoints compared to semaglutide 1 mg.
The (NNT) for all doses of tirzepatide was statistically significantly lower than for semaglutide for individual and composite endpoints, except for some cases with the 5 mg dose.
Simplified
INTRODUCTION: Achieving glycemic control can help reduce complications of type 2 diabetes (T2D). This study compared the pharmacy and (NNT) of tirzepatide 5 mg, 10 mg, and 15 mg versus semaglutide 1 mg to achieve glycemic, weight loss, and composite treatment endpoints in patients with T2D in the United States.
METHODS: The proportions of patients achieving glycemic, weight loss, and composite treatment endpoints were obtained from the phase 3 SURPASS-2 randomized clinical trial which compared tirzepatide 5 mg, 10 mg, and 15 mg to semaglutide 1 mg. Annual pharmacy costs were calculated using 2022 wholesale acquisition costs. Cost per responder and NNT were calculated along with 95% confidence intervals and tests for statistical significance (P ≤ 0.05).
RESULTS: Tirzepatide had a lower cost per responder to achieve glycated hemoglobin A1c (HbA1c) endpoints of ≤ 6.5% (10 mg and 15 mg doses) and < 5.7% (all doses) and weight loss endpoints of ≥ 5% (10 mg and 15 mg doses), ≥ 10% (all doses), and ≥ 15% (all doses). The cost per responder to achieve HbA1c < 7% (all doses of tirzepatide) and ≤ 6.5% (5 mg tirzepatide) were not statistically significantly different between tirzepatide and semaglutide 1 mg. The cost per patient to achieve the composite endpoints (HbA1c < 7.0%, ≤ 6.5%, or < 5.7%/weight loss ≥ 10%/no hypoglycemia) was statistically significantly lower for all doses of tirzepatide than for semaglutide 1 mg. The NNTs for all doses of tirzepatide were statistically significantly lower than that for semaglutide 1 mg to achieve all individual and composite endpoints, with the exception of the 5 mg dose for HbA1c < 7.0% and HbA1c ≤ 6.5%, where tirzepatide had numerically lower NNTs that were not statistically significant.
CONCLUSION: Tirzepatide is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) that may offer the potential to achieve stringent glycemic goals, weight loss targets, and composite treatment goals at a lower cost per responder compared to semaglutide 1 mg among people with T2D.
Key numbers
$15,936
for HbA1c ≤ 6.5%
Cost for tirzepatide 10 mg to achieve HbA1c ≤ 6.5%
$35,478
for Weight Loss ≥ 15%
Cost for tirzepatide 15 mg to achieve weight loss ≥ 15%
2.19
for HbA1c < 5.7%
for tirzepatide 15 mg to achieve HbA1c < 5.7%
Full Text
We can’t show the full text here under this license.
